Zolgensma First To Be Subject To New German Data Collection Rules
Price & Reimbursement Body Sets Out New Process
Executive Summary
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
You may also be interested in...
Gene Therapy Pricing To Come Under Microscope In Germany
The G-BA, the body in charge of Germany’s pricing and reimbursement process, has confirmed that Novartis’s gene therapy Zolgensma (onasemnogene abeparvovec) offers no additional benefit over Biogen’s Spinraza (nusinersen) for treating spinal muscular atrophy.
Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy, while Roche’s Evrysdi offers a hint of benefit in one patient group.
German Guidelines Seek To Boost Biosimilar Uptake
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.